Navigation Links
Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign
Date:2/29/2008

ips. One hundred percent of the funds raised by Jiffy Lube are donated to the Go Red For Women movement.

"Heart disease is a 365 day-a-year problem and one in three women has some form of cardiovascular disease," said Jennifer H. Mieres, M.D., Go Red For Women spokesperson and director of Nuclear Cardiology and associate professor of medicine at New York University. "There is a significant and ongoing need for more research and development so we can reduce the impact of heart disease. We are thrilled with the support we have received so far from Jiffy Lube and its customers, and look forward to continued success through this relationship."

The Jiffy Lube Maintenance Partners for Life campaign leverages the strong parallels between properly maintaining both heart health and vehicle health, and educates people on smart preventive maintenance of their bodies and vehicles. People can visit http://www.JiffyLube.com/GoRedForWomen to learn more about Maintenance Partners for Life and find a participating Jiffy Lube service center in their area. They can also take the Maintenance Partners for Life Car CheckUp to help assess how well they are tending to their vehicle's needs. To find your local Jiffy Lube location, visit http://Locations.JiffyLube.com.

About Maintenance Partners for Life

Jiffy Lube, America's largest fast-lube company, and the American Heart Association (AHA) are working together to fight heart disease. Through Jiffy Lube's Maintenance Partners for Life campaign, the goal is to raise more than $1 million dollars for the AHA's Go Red For Women movement, which celebrates the energy, passion and power women have to band together and eradicate heart disease.

About Go Red For Women

Since 2004, Go Red For Women has captured the energy, passion, and intelligence of women to work collectively to wipe
'/>"/>

SOURCE Jiffy Lube
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Jiffy Lube(R) Aims to Raise $1 Million for American Heart Associations Go Red For Women(TM) Movement
2. Billians HealthDATA(R) Continues to Delight Their Customers with Comprehensive Cutting Edge Healthcare Market Intelligence
3. Childrens Hospital Heart Center Continues to Expand Outreach Efforts to Increase Access to Quality Care for More Families
4. Greenway Medical Technologies Continues Record Setting Growth
5. Consumer Driven Healthcare Continues To Make Its Mark on Indianapolis Market
6. Bone mineral content continues to increase in obese adolescents during weight loss
7. Ford Motor Company Fund Continues Longtime Support to Cancer Care
8. Data Show ARIMIDEX(R) (Anastrozole) Continues To Be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer
9. HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sams Club in Richmond Hill, Ontario
10. Cryoablation continues to show good results for kidney cancer patients
11. DNC: Romneys Health Care Confusion Continues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...tiretroviral therapy may be due to genetic factors... A new study challenges the long-held belief that ...tem,s ability to restore itself after HIV patients...rapy (HAART). , From 50 percent to 90 percent o...CV. Intravenous drug use is the main cause of both...
(Date:7/25/2008)...ng overweight or obese is not only a personal issu...ealth issue that impacts other people in society. ...ch reveals that the extra Medicare cost associate...nificant financial burden on tax payers, costing u...tire current Medicare population. , The article...
(Date:7/25/2008)... consumers tips and encourages them to, ,Speak Up...., July 25 /PRNewswire-USNewswire/ -- The Pennsylv...onal Patient Safety Day" which,is a national effor...icipate fully in their healthcare by asking questi...urgery or illness., "We understand the important ...
(Date:7/25/2008)...the number of jobs created in the medical field sl...different kind of slowdown: they laid off fewer pe... Seattle, WA (PRWEB) July 25, 2008 -... field slowed in June overall, pharmaceutical comp...ill be music to the ears of sales representatives:...
Breaking Medicine News(10 mins):Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3
...t first glance, it is difficult to believe anyone ... of Germans bathe in them every year to benefit th...tory as a natural cure. Patients have sought out ... in Brandenburg for more than a century, originall...
... trial of Aranesp an anemia drug from Amgen Inc di...dvanced cancer patients. This has reiterated the f...ricted conditions only. The mode of action of Ara...led erythropoietin (EPO) which augments the produc...
... first study, appearing in the February issue of R...to study the brains of a large group of babies// s...n and around the brains of one in four babies who ...ds in and around the brain are very common in infa...
...ird flu has come to Russia after quarantine measur...flu in 2006 resulted in an epidemic that called fo... outbreak is near the country’s Black Sea coast. ...vered the H5N1 bird flu virus in poultry at three ...
Other Medicine News:Health News:Germany's Therapeutic Mud Baths Have Healing Qualities 2Health News:Risk of Hemorrhage Increased in Vaginally Born Babies 2
(Date:7/24/2008)...W, Calif., July 24 /- Alexz... today that it has initiated,its second Phase 3 cl...Z-004 is an inhalation product candidate being dev...ients with schizophrenia or bipolar disorder.,Alex...id pharmacokinetic,(PK) properties resulting from ...
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Headlines claim...he whole story. The small scale,preliminary study...n,Reproduction, is based on recollected intake of ...oods. "This study is confounded by many,issues, th...t deal of,caution," warned Dr. Tammy Hedlund, a re...
(Date:7/24/2008)...y thermometer designed to take body temperature, f...-- Kidz-Med, Inc.,(subsidia...ts: ASFX),United States distributor of the Thermo...d to announce the results of a clinical study,cond...rsity of Milan, in,Milan, Italy, which proves that...
(Date:7/24/2008)...OLIS, France, July 24 /- Ni... top-line results from the 52-week,open label safe...letion of,the 301 phase 3 study for naproxcinod. T...and efficacy was maintained for the one-year durat...bal assessment scale. In,addition, the results sho...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Mylan Restores Availability of Generic Levothyroxine in Florida 11381 1Mylan Restores Availability of Generic Levothyroxine in Florida 11381 2Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 1Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 2Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 3Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 4Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 5Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 6Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 7Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 8Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 9Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 1Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 2Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 3Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 4Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 5Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 6Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 7Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 8Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 9Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 10Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 11Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 12Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 13Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 14Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 15Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 16Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 17Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 18Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 19Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 20Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 21Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 22Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 23Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 24Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 25Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 26Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 27Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 28Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 29Roche Purchases Shares in Tender Offer for Ventana 11373 1Roche Purchases Shares in Tender Offer for Ventana 11373 2Roche Purchases Shares in Tender Offer for Ventana 11373 3Roche Purchases Shares in Tender Offer for Ventana 11373 4
...xas--(BUSINESS WIRE)--Jun 27, 2007 - Opexa,Therape...he,development and commercialization of cell thera...ternational Society for Stem Cell,Research Annual ...rom June 17-20 and at the 13th Annual Meeting of t...T) in Sydney, Australia from June,24-27. The two p...
...SS WIRE)--Jun 27, 2007 - Gentium S.p.A. (Nasdaq:,G...nd preclinical,data that support the safety, activ...Defibrotide in combination with anticancer,therapy... an update,from the Company,s ongoing Phase I/II c...psed multiple myeloma with Defibrotide in,combinat...
Other Medicine Technology:Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 2Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 3Gentium's Defibrotide Seen as Active in Multiple Myeloma 2Gentium's Defibrotide Seen as Active in Multiple Myeloma 3
For the measurement of vaginal pH as part of a self examination programme to help reduce the risk of pre-term birth
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens
ZyDoc offers a full medical transcription and documentation solution.
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
Medicine Products: